Login / Signup

Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update.

Naren RamakrishnaCarey K AndersNancy U LinAki MorikawaSarah TeminSarat ChandarlapatyJennie R CrewsNancy E DavidsonMaria Alice B FranzoiJeffrey J KirshnerIan E KropDebra A PattJane PerlmutterSharon H Giordano
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Memantine and hippocampal avoidance should be added to whole-brain radiotherapy when possible. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment onto a clinical trial, and/or palliative care. There are insufficient data to recommend for or against performing routine magnetic resonance imaging to screen for brain metastases; clinicians should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer.Additional information is available at www.asco.org/breast-cancer-guidelines.
Keyphrases